FDA-cleared profile

SmartChest

Milvue · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Clinical role
Passive notification and worklist prioritization in parallel with standard of care; the device does not send a proactive alert, reorder or remove cases, or direct attention to a specific image location.
Images and patients
X-ray/Radiography · Chest/lung
Key limitation
Keep in mind: Prioritization only; the contextual notification is not diagnostic, is not intended for standalone clinical decision-making, and is not a rule-out result. Unflagged studies still require specialist interpretation, the device does not direct attention to a specific image portion, and out-of-scope views or ages are not processed.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/lung Input: Frontal PA or AP chest X-ray images from transitional adolescents aged 18-21 and adults aged 22 years and older, received from PACS or other DICOM storage; lateral views and excluded ages are not processed.
  • Who uses it?Intended users: Appropriately trained medical specialists qualified to interpret chest radiographs
  • What does the software produce?Output: A newly generated DICOM secondary-capture series with study-level status and tags such as CASE PROCESSED, NOT PROCESSED, SUSPECTED FINDING, SUSPECTED PLEURAL EFFUSION, and SUSPECTED PNEUMOTHORAX, plus the number of images received and processed.
  • What is its most important limitation?Key limitation: Prioritization only; the contextual notification is not diagnostic, is not intended for standalone clinical decision-making, and is not a rule-out result. Unflagged studies still require specialist interpretation, the device does not direct attention to a specific image portion, and out-of-scope views or ages are not processed.

Clinical takeaway. Clinical role: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Evidence takeaway. Evidence from the reviewed source record: FDA K232410 reports two independent standalone performance assessments, each using 300 US chest X-ray cases and a reference standard formed by majority consensus of three ABR-certified cardiothoracic radiologists. For pneumothorax, AUC was 0.989, sensitivity 92.7% (95% CI 87.4-96.2), and specificity 97.3% (95% CI 93.4-99.1). For pleural effusion, AUC was 0.975 (95% CI 0.960-0.987), sensitivity 93.3% (95% CI 88.1-96.4), and specificity 90.0% (95% CI 84.1-94.1). Execution time was reported separately for local and cloud servers.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Passive notification and worklist prioritization in parallel with standard of care; the device does not send a proactive alert, reorder or remove cases, or direct attention to a specific image location.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Frontal PA or AP chest X-ray images from transitional adolescents aged 18-21 and adults aged 22 years and older, received from PACS or other DICOM storage; lateral views and excluded ages are not processed.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
A newly generated DICOM secondary-capture series with study-level status and tags such as CASE PROCESSED, NOT PROCESSED, SUSPECTED FINDING, SUSPECTED PLEURAL EFFUSION, and SUSPECTED PNEUMOTHORAX, plus the number of images received and processed.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Standard-of-care chest-radiography workflow using a PACS or worklist; facility type is not specified in the FDA packet
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Appropriately trained medical specialists qualified to interpret chest radiographs
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Prioritization only; the contextual notification is not diagnostic, is not intended for standalone clinical decision-making, and is not a rule-out result. Unflagged studies still require specialist interpretation, the device does not direct attention to a specific image portion, and out-of-scope views or ages are not processed.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K232410 reports two independent standalone performance assessments, each using 300 US chest X-ray cases and a reference standard formed by majority consensus of three ABR-certified cardiothoracic radiologists. For pneumothorax, AUC was 0.989, sensitivity 92.7% (95% CI 87.4-96.2), and specificity 97.3% (95% CI 93.4-99.1). For pleural effusion, AUC was 0.975 (95% CI 0.960-0.987), sensitivity 93.3% (95% CI 88.1-96.4), and specificity 90.0% (95% CI 84.1-94.1). Execution time was reported separately for local and cloud servers.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K232410 reports two independent standalone performance assessments, each using 300 US chest X-ray cases and a reference standard formed by majority consensus of three ABR-certified cardiothoracic radiologists. For pneumothorax, AUC was 0.989, sensitivity 92.7% (95% CI 87.4-96.2), and specificity 97.3% (95% CI 93.4-99.1). For pleural effusion, AUC was 0.975 (95% CI 0.960-0.987), sensitivity 93.3% (95% CI 88.1-96.4), and specificity 90.0% (95% CI 84.1-94.1). Execution time was reported separately for local and cloud servers.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Pneumothorax: 92.7% (95% CI 87.4%-96.2%); pleural effusion: 93.3%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

Condition-specific FDA endpoints are retained separately rather than collapsed into one device-level pair.

Reported specificity
Pneumothorax: 97.3% (95% CI 93.4%-99.1%); pleural effusion: 90.0%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

Condition-specific FDA endpoints are retained separately rather than collapsed into one device-level pair.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

SmartChest regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K232410
  • Samplen=300
  • IndependenceIndependence not established

K232410

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232410. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Frontal PA or AP chest X-ray images from transitional adolescents aged 18-21 and adults aged 22 years and older, received from PACS or other DICOM storage; lateral views and excluded ages are not processed.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K232410: SmartChest

  2. Routing

    Source context, not route validation: Chest radiographs are automatically received from PACS or other DICOM storage and results are passively returned as a new DICOM series to the worklist platform. The packet describes local and cloud server execution contexts but does not establish a specific PACS/RIS interface, version, or current deployment model.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K232410: SmartChest

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-13 ·

  4. Returned objects

    Source context, not route validation: A newly generated DICOM secondary-capture series with study-level status and tags such as CASE PROCESSED, NOT PROCESSED, SUSPECTED FINDING, SUSPECTED PLEURAL EFFUSION, and SUSPECTED PNEUMOTHORAX, plus the number of images received and processed.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K232410: SmartChest

  5. Viewer/worklist/report

    Unresolved route: A newly generated DICOM secondary-capture series with study-level status and tags such as CASE PROCESSED, NOT PROCESSED, SUSPECTED FINDING, SUSPECTED PLEURAL EFFUSION, and SUSPECTED PNEUMOTHORAX, plus the number of images received and processed.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K232410: SmartChest

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Chest radiographs are automatically received from PACS or other DICOM storage and results are passively returned as a new DICOM series to the worklist platform. The packet describes local and cloud server execution contexts but does not establish a specific PACS/RIS interface, version, or current deployment model.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for SmartChest; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232410
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest/lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-05-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K232410 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-11-13 - Exact FDA submission

    A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K232410: SmartChest

    U.S. Food and Drug Administration - Published 2024-05-10 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SmartChest model card (K232410)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K232410

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K232410 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21
FDA-cleared K231871

Radify Triage

Envisionit DeepAI Ltd

Authorized purpose: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2024-01-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history